Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye F, Dewanjee S, Li Y, Jha NK, Chen Z-S, Kumar A, Vishakha BT, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:1–40.

Article  Google Scholar 

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:1–37.

Article  Google Scholar 

Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexopoulos G, Zhang J, Karampelas I, Patel M, Kemp J, Coppens J, Mattei TA, Mercier P. Long-term time series forecasting and updates on survival analysis of glioblastoma multiforme: a 1975–2018 Population-Based Study. Neuroepidemiology. 2022;56:75–89.

Article  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

Article  CAS  PubMed  Google Scholar 

Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

Article  CAS  PubMed  Google Scholar 

Mancini A, Xavier-Magalhães A, Woods WS, et al. Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner. Cancer Cell. 2018;34:513-528.e8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.

Article  CAS  PubMed  Google Scholar 

Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60.

Article  CAS  PubMed  Google Scholar 

Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836–48.

Article  CAS  PubMed  Google Scholar 

Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery. 2012;71:201–22 (discussion 222–3).

Article  PubMed  Google Scholar 

Rong Y, Durden DL, Van Meir EG, Brat DJ. “Pseudopalisading” necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65:529–39.

Article  PubMed  Google Scholar 

Geindreau M, Ghiringhelli F, Bruchard M. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci. 2021;22:4871.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gillette JS, Wang EJ, Dowd RS, Toms SA. Barriers to overcoming immunotherapy resistance in glioblastoma. Front Med. 2023;10:1175507.

Article  Google Scholar 

Dubinski D, Wölfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, Wiendl H, Grauer OM. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol. 2015;18:807–18.

Article  PubMed  PubMed Central  Google Scholar 

Chongsathidkiet P, Jackson C, Koyama S, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24:1459–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schaettler M, Richters M, Griffith M, Dunn G. Characterization of the genomic and immunological diversity of malignant human brain tumors through multi-sector analysis. J Immunol. 2020;204:242.45-242.45.

Article  Google Scholar 

Mahlokozera T, Vellimana AK, Li T, et al. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro Oncol. 2018;20:472–83.

Article  CAS  PubMed  Google Scholar 

Neftel C, Laffy J, Filbin MG, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178:835-849.e21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103:1139–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anandasabapathy N, Victora GD, Meredith M, et al. Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain. J Exp Med. 2011;208:1695–705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sung S-SJ. Monocyte-derived dendritic cells as antigen-presenting cells in T-cell proliferation and cytokine production. Methods Mol Biol. 2019;2020:131–41.

Article  CAS  PubMed  Google Scholar 

McMahon EJ, Bailey SL, Miller SD. CNS dendritic cells: critical participants in CNS inflammation? Neurochem Int. 2006;49:195–203.

Article  CAS  PubMed  Google Scholar 

Bowman-Kirigin JA, Desai R, Saunders BT, et al. The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive antitumor immunity in the brain. Cancer Immunol Res. 2023;11:20–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mrdjen D, Pavlovic A, Hartmann FJ, et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity. 2018;48:380-395.e6.

Article  CAS  PubMed  Google Scholar 

Jackson CM, Kochel CM, Nirschl CJ, et al. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin Cancer Res. 2016;22:1161–72.

Article  CAS  PubMed  Google Scholar 

Coxon AT, Desai R, Patel PR, et al. A pilot study of lymphoscintigraphy with tracer injection into the human brain. J Cereb Blood Flow Metab. 2023;43:1382–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghouzlani A, Kandoussi S, Tall M, Reddy KP, Rafii S, Badou A. Immune checkpoint inhibitors in human glioma microenvironment. Front Immunol. 2021;12:679425.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7:e1364828.

Article  PubMed  PubMed Central  Google Scholar 

Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.

CAS  PubMed  Google Scholar 

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1–14.

Article  CAS  Google Scholar 

Khasraw M, Reardon DA, Weller M, Sampson JH. PD-1 Inhibitors: do they have a future in the treatment of glioblastoma? Clin Cancer Res. 2020;26:5287–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Youssef G, Dietrich J. Ipilimumab: an investigational immunotherapy for glioblastoma. Expert Opin Investig Drugs. 2020. https://doi.org/10.1080/13543784.2020.1826436.

Article  PubMed  Google Scholar 

Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1003–10.

Article  PubMed  Google Scholar 

Omuro A, Brandes AA, Carpentier AF, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2022;25:123–34.

Article  PubMed Central  Google Scholar